Video

Dr. Marks on how PSMA imaging is “opening doors” in prostate cancer

Author(s):

Urology Times staff

“We call this a ‘disruptive innovation,’” says Leonard S. Marks, MD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Leonard S. Marks, MD, explains how the Journal of Urology review on prostate-specific antigen membrane imaging for prostate cancer will affect urologists and patients alike. Marks is a deKernion Endowed Chair in Urology at the David Geffen School of Medicine at the University of California, Los Angeles.

      Related Videos
      Human kidney stones | Image Credit: © freshidea - stock.adobe.com
      Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
      De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
      De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
      Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
      Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
      Woman talking with doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
      Alternative treatments and patient communication for genitourinary syndrome of menopause
      Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
      Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
      Prostate cancer screening: Expert weighs in after Biden's diagnosis
      Prostate cancer screening: Expert weighs in after Biden's diagnosis
      Sarah Razavi, MD, answers a question during a Zoom video interview
      Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Study results affirm effectiveness of evolving prostate cancer therapies
      Laura Davis, MD, on link between microplastics and bladder cancer
      Laura Davis, MD, on link between microplastics and bladder cancer
      Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
      Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
      Related Content
      Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617
      April 8th 2025

      Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617

      Phillip Kuo, MD, PhD Hannah Clarke
      "For every 1 unit increase in whole body tumor SUVmean, there was a 12% decrease in the risk of an rPFS event and a 10% decrease in the risk of death," says Phillip H. Kuo, MD, PhD, FACR.
      Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
      June 22nd 2023

      Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

      Urology Times staff
      "We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
      18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates
      March 31st 2025

      18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates

      Phillip Kuo, MD, PhD
      "I think a take-home message there is that in the prostate/prostate bed, you have to take extra time and caution in reading that region," says Phillip H. Kuo, MD, PhD.
      Study finds geographic disparities in MRI use in prostate cancer
      March 27th 2025

      Study finds geographic disparities in MRI use in prostate cancer

      Hannah Clarke
      The use of pre-diagnostic MRI was 3.8% in 2012, which increased to 32.6% in 2019.
      FDA approves PET imaging product Gozellix for prostate cancer
      March 20th 2025

      FDA approves PET imaging product Gozellix for prostate cancer

      Hannah Clarke
      Gozellix – after radiolabeling with 68Ga – is indicated for PET imaging of PSMA positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and those who have suspected recurrence based on an elevated serum prostate-specific antigen level.
      64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer
      March 6th 2025

      64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer

      Hannah Clarke
      The detection rate ranged from 44% to 58% on day 0 and 58% to 80% on day 1.
      © 2025 MJH Life Sciences

      All rights reserved.